Case details

CCENT/2010/34 - Grifols / Talecris

Grifols, S.A.

the parent company of a group composed of over 40 companies operating worldwide in the health sector, in three divisions: Bioscience (mainly engaged in research into and the development, production and marketing of plasma derivatives); Diagnostics (mainly active in research into and the development, production and marketing of diagnostic products for clinical analyses, including products for blood banks in hospitals and transfusion centres); and the Hospital division (which supplies a wide range of non-biological products used in hospital pharmacies, surgery, clinical nutrition, fluid therapy and other therapies). Grifols is represented in Portugal by a subsidiary that distributes and sells Grifols products, including plasma derived products, and provides after-sales technical assistance.

Talecris Biotherapeutic Holdings Corp.

operates worldwide in the biotherapeutic and biotechnology field, which investigates, develops and produces vital treatments for people with potentially fatal disorders in different therapeutic areas, e.g. immunodeficiency, neurology, alpha-1 antitrypsin (AAT) deficiency and haemophilia, among others. It has no subsidiary or representative in Portugal: it markets its products through a distributor.

Art. 9(1)(a) (Law 18)

Market share

Conglomerate

Closed

Phase 1

Publication of the announcement - The Spanish health care enterprise Grifols SA ("Grifols") notifies acquisition of exclusive control of the American undertaking Talecris Biotherapeutic Holdings Corp. ("Talecris"), by means of the acquisition of the whole of the latter?s registered capital.